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Surgical aortic valve replacement used for patients with aortic
stenosis reduces symptoms and improves survival, operative
mortality is generally low. But, about one-third of patients
with severe aortic stenosis are not candidates for surgical
replacement due to older age, left ventricular dysfunction or
other comorbidities. Therefore, availability of aortic valve
replacement using transcatheter technology opened quite
new option for improvement of lives of patients with aortic
valve stenosis. This procedure (transcatheter aortic valve
implatation—TAVI) was introduced by Cribier in 2002 [1],
since then started the widespread use of this procedure, used
for treatment for specific group of high-surgical-risk patients
with symptomatic aortic stenosis [2,3]. This year we celebrate
ten year experience with TAVI, over 20,000 cases performed
and long list of publications on this topic published.
Currently, two TAVI systems are commercially available: the
Edwards transcatheter heart valve (THV) SAPIEN XT system
which consists of three bovine pericardial leaflets mounted
on low profile Novaflex delivery system—a tubular slotted
stainless steel, balloon expandable stent, which is optimally
placed in the subcoronary position. The second is the
CoreValve ReValving System which consists of three porcine
pericardial leaflets mounted on self-expanding multistage
nitinol frame, and housed in low profile percutaneous
delivery catheter. The specific feature of CoreValve device is
that it is anchored not only within aortic bulbus, but extends
in the supracoronary area, where it is also anchored. Both
systems are currently available with low profile delivery
catheters, which means that they could be used in majority
of patients with aortic stenosis [4]. Procedural success was
initially about 80%, in most recent series increased to over
95% [5,6], thirty-day survival from registries is reffered
between 90% and 95%.
In this issue of the journal Neˇmec et al. report their results
of comparison of the surgical and transcatheter aortic valve
replacement in high risk patients [7]. In the small group of 45
patients (mean age 82 years) with severe aortic stenosis they
compare three modalities of treatment: 15 patients under-
went surgical valve replacement, 30 patients had TAVI—eitheresearch Grant PRVOUK-P35/LF1/5.transfemoral (15 patients) or antegrade transapical (15
patients) approach. Technically, all procedures have been
successful, there were 7 complications during TAVI, in 30 day
after procedure only one patient died due to sepsis after
surgical replacement, one year survival was 86.3%. Authors
emphasized, that overall results and frequency of complica-
tions were similar in transfemoral as well as transapical
approach. They concluded that TAVI is a safe procedure, with
results comparable with surgery in high-risk group of patients
with severe aortic stenosis.
Data about TAVI use in the last years are fast growing, and
results of the procedure are promising, current experience
with TAVI is summarized in this editorial. When focused on
available data we can see, that the first and still the only one
randomized trial with TAVI is PARTNER Trial [8,9], a lot of
informations were published from results of several non-
randomized studies and registries [10,11].2. PARTNER trial
PARTNER trial (Placement of Aortic Transcatheter Valves) was
a multicenter randomized clinical trial, which compared
standard surgical therapy—first part of the trial, or standard
non-surgical therapy—second part of the trial with TAVI
procedure. In surgical part of the trial [9], 699 high-risk
patients with severe aortic stenosis were randomized to
either surgical or catheter transfemoral aortic valve replace-
ment. The rates of death were similar in both groups at 30 day
as well as at one-year follow-up (6.5% surgery, 3.4% TAVI at
30 day, 26.8% surgery, resp., 24.2% TAVI at 1 year). Main
periprocedural adverse events in surgical group were major
bleeding and new onset of atrial fibrilation, there was higher
stroke rate in TAVI group (3.8% resp. 2.1%). In second (non-
surgical) part of the trial [8] authors assigned randomly 358
patients with severe aortic stenosis not suitable for surgery
into two groups: it was either standard therapy including
balloon aortic angioplasty (performed in 83.8% of patients), or
TAVI procedure using transfemoral approach. When com-
pared to standard therapy, patients with TAVI showed
significant reduction of mortality from any cause at one
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standard group (44.6% from cardiovascular causes). When
compared to data of Czech authors, presented in this issue [7],
survival rates at one year are lower than in the PARTNER trial
(13.3% vs 24.2%).3. Non-randomized studies and registries
Several non-randomized studies and registries documented
safety and efficacy of TAVI, they also showed improvement in
functional class, quality of life and positive changes in
gradient on aortic valve as well as increase of aortic valve
area after TAVI [3,9,12,13]. The success rate rised with
increasing experience from initial 75% up to 93–98% in
currently referred series [14,15]. The mortality rates are also
decreasing with increasing experience of operating teams,
30 day survival is 85–95%, one-year survival rate ranges
between 70% and 85%. Predictive for mortality are mainly
comorbidities, such as pulmonary hypertension, severe
mitral regurgitation, need for hemodynamic support during
and after procedure, as well as post-procedural sepsis and
chronic kidney disease [12,16]. Contrary, there are also several
conditions which favor TAVI against surgery: TAVI is excellent
alternative to surgical replacement of aortic valve in patients
with reduced left ventricular ejection fraction (LVEF), the
greater reported increase in LVEF with the TAVI is probably
due to better improvement in aortic valve hemodynamics
[17]. A possible promising indication of TAVI is catheterization
treatment of bioprosthesis which developed degenerative
changes. Since bioprosthetic valves are used in elderly
patients, who suffer more often with severe comorbidities,
TAVI treatment option is preferred alternative approach
and has been qalready successfuly used in this group of
patients [18].4. Summary
Transcatheter aortic valve implantation emerged in 2002 as
new modality of treatment in high-surgical-risk patients
with severe aortic valve stenosis. Since its introduction TAVI
procedure was continually integrated into daily clinical
practice and today is becoming the standard of care for
symptomatic patients with severe aortic stenosis who are not
surgical candidates. When compared to surgical treatment,
TAVI showed similar procedural success as well as similar
rate of major complications, also survival rates up to one
year are comparable. Great importance must be stressed on
patients indications, proper training of operators and close
cooperation of cardiologist, surgeons and intensive care
professionals. Today, transcatheter valve technology is
used not only in aortic stenosis, but also in patients with
pulmonary conduit valve dysfunction (Melody transcuta-
neous pulmonary valve), same Melody valve was also used
in stenotic or regurgitant tricuspid valves (off label indica-
tion). Other transcatheter procedures are performed for
percutaneous mitral valve repair [19]. Those are new chal-
lenges for interventional cardiologist, future will show,whether we will be able to use them for the benefit of our
patients.
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